For most parents, a newborn screening result is the first time they have ever heard the word galactosemia. The diagnosis can feel overwhelming, and the medical terminology terrifying. But according to Akihiro Asai, M.D., Ph.D., a researcher and pediatric hepatologist at Cincinnati Children’s Hospital, understanding what is happening in a baby’s body and acting quickly on that knowledge can make an enormous difference in outcomes.

Galactosemia is a rare genetic condition in which the body lacks the enzyme needed to break down galactose, a sugar found in milk. Without that enzyme, galactose converts into a toxic compound that accumulates in the body and damages vital organs, particularly the liver. The good news is that a swift dietary switch can stop that toxic buildup before it causes lasting harm. The harder truth is that even with lifelong dietary adherence, some children still face ongoing challenges that require a comprehensive, specialized care team and, increasingly, the promise of emerging therapies that could one day change the treatment landscape entirely.

In partnership with the American Liver Foundation and its 30-Day Meal Plan, Asai walks us through what families need to know, from hidden dietary triggers to the gene therapy research quietly reshaping what is possible for children with galactosemia.

Arepas with Veggies

Ingredients:

• 1 cup precooked cornmeal
• 1 cup water
• 1 cup diced bell peppers
• 1/2 cup diced onions
• 1 teaspoon olive oil

Directions:

1. In a medium bowl, mix cornmeal with water to form a dough.
2. Divide the dough into 4 equal patties and cook in a pan with olive oil for 3-4 minutes on each side or until brown.
3. Top with bell peppers and onions. You can choose to sauté these in the pan you used to make the arepas or eat them raw. Serve warm and enjoy!

For a family who has just received a newborn screening result indicating galactosemia, the medical terminology can be terrifying. In plain language, what is physically happening in a baby’s body when they cannot break down galactose, and why is an immediate dietary switch so critical?

Akihiro Asai, M.D., Ph.D.: Galactosemia is a condition in which the body lacks a specific enzyme needed to break down galactose, a sugar found in milk. Because the body cannot digest galactose, it instead turns this sugar into a toxic chemical that can build up over time. This buildup causes damage to vital organs, particularly the liver, and can lead to cataracts. However, as long as patients and babies switch to a galactose-free formula or diet and stick to safe sugars like glucose, this toxic chemical does not form, allowing them to process their nutrition properly and grow normally.

What are some of the most common hidden dietary triggers that parents need to look out for on ingredient labels?

AA: Parents should be vigilant when reading ingredient labels for hidden triggers such as casein (cow milk proteins), which may also appear in the inactive ingredients of children’s medications and supplements. While it’s important to be cautious, trace amounts of galactose rarely cause significant issues and shouldn’t overshadow the critical need to expose babies to various textures to develop healthy oral sensation and motor skills. Consulting with a genetic dietitian or a specialist in metabolic diseases provides the best guidance for selecting safe foods and medications, ensuring both safety and proper growth and development.

Even with a strict, lifelong dairy-free diet, many children with classic galactosemia still face ongoing challenges as they grow. Can you explain why these long-term complications can still occur despite good dietary adherence?

AA: The long-term complications of galactosemia arise from metabolic disruptions (chemical chain reactions in the cells) that persist despite strict dietary restriction. The body naturally produces galactose, which leads to the accumulation of galactose-1-phosphate (a toxic metabolite) that inhibits other important enzymes. Also, this process generates galactitol, which causes osmotic damage and oxidative stress in critical tissues such as the brain and ovaries. This metabolic stress reduces essential protein processing and impairs brain, kidney and ovarian functions. Ultimately, these factors, alongside early tissue toxicity, drive the widespread cellular dysfunction responsible for long-term complications like speech delays and early onset ovarian insufficiency.

What should a comprehensive care team look like for a growing child, and how can parents partner with speech therapists, dietitians and developmental pediatricians early on to support their child’s milestones?

AA: A comprehensive care team for a growing child with complex metabolic or genetic conditions relies heavily on specialized genetic dietitians, who are typically based at academic children’s hospitals rather than general pediatric clinics. Trained in specific inborn errors of metabolism, such as galactosemia, these subspecialists possess the clinical expertise needed to design nutrition plans tailored to a child’s age-appropriate developmental stage while strictly avoiding harmful compounds. Because these experts are rare and heavily clustered at major medical centers, patient advocacy groups actively push for cross-state licensure and insurance exceptions so families can more easily access their critical consulting services via telemedicine.

For decades, the only management tool for galactosemia was dietary restriction. What exciting research, clinical trials or emerging enzyme-targeted therapies are on the horizon that might offer families new ways to protect their children’s long-term health and neurological development?

AA: The development of gene therapy for classic (Type 1) galactosemia focuses on restoring functional galactose-1-phosphate uridylyltransferase (GALT) enzyme activity to address the root genetic cause of the disease.

Because a standard galactose-restricted diet cannot prevent long-term cognitive, speech and neurological complications, researchers are designing genetic solutions to eliminate the systemic accumulation of toxic metabolites. Preclinical research has focused on adeno-associated virus (AAV) vectors to deliver a healthy copy of the human GALT gene directly into cells. Animal models treated with these investigational therapies have demonstrated promising results, including reductions in toxic metabolites in critical organs such as the liver and brain. While these pipeline programs move closer to human trials, scientists continue to carefully evaluate critical factors related to long-term safety, barriers to targeted delivery and optimal therapeutic dosing windows to ensure that future treatments are both highly effective and safe.